Protalix BioTherapeutics Announces Positive 12-Month Interim Data From BRIDGE Phase III Open Label Switch-Over Study Showing Pegunigalsidase Alfa For The Treatment Of Fabry Disease Was Well Tolerated
Benzinga Newsdesk